INTRODUCTION {#s1}
============

Nasopharyngeal carcinoma (NPC) is an endemic disease in southern China. The incidence of stage II NPC has greatly increased with improvements in diagnosis. Radiotherapy (RT) or concurrent chemoradiotherapy (CCRT) are the primary treatment modalities for stage II NPC. CCRT is recommended by the National Comprehensive Cancer Network, but the evidence is weak \[[@R1]--[@R4]\]. However, RT is recommended by the Chinese Anti-Cancer Association because CCRT does not improve survival, but increases toxic reactions \[[@R5]--[@R9]\]. The best treatment modality is still controversial.

After treatment, the 5-year disease-specific survival rate is as high as 97.3% for stage II NPC \[[@R7]\]. The high survival rate makes QoL increasingly important. Clinicians should pay more attention to QoL because long-term survivors may have problems with swallowing, hearing, and speech, as well as psychological and functional problems. However, previous studies mainly focused on endpoints of overall survival, disease-free survival, or local control rate \[[@R1]--[@R9]\]. These endpoints lack information on patients' experience with treatment-related toxicities or QoL.

We conducted a cross-sectional study to compare the QoL of patients with stage II NPC treated with RT versus CCRT. The result of this study might help clinicians make treatment decisions and provide information to health workers on which health services are most beneficial.

RESULTS {#s2}
=======

Patients {#s2_1}
--------

From June 2008 to June 2013, 235 patients with stage II NPC received radical treatment in the Cancer Hospital of Guangxi Medical University. This study excluded 129 patients. Among the excluded patients, 8 were lost to follow-up, 4 received induced chemotherapy, 40 received adjuvant chemotherapy, 5 died, 9 were loco-regional failures, 7 were distant failures, 51 were non-compliant, and 5 did not complete the questionnaire. We included 106 patients treated with RT (n = 55) or CCRT (n = 51). Disease-free survival of all subjects was more than 3 years. Table [1](#T1){ref-type="table"} summarizes patient characteristics.

###### Patient characteristics

                       RT (n = 55)   CCRT (n = 51)   *P*
  -------------------- ------------- --------------- -------
  Gender                                             
   Male                38 (69.10%)   32 (62.75%)     0.473
   Female              17 (30.90%)   19 (37.25%)     0.739
  Age (years)                                        
   Median              43            42              0.915
   Range               27-68         22-64           
  Follow-up (months)                                 
   Median              62            48              0.000
   Range               42-89         38-62           
  AJCC stage                                         
   T1N1M0              10 (18.18%)   11 (21.57%)     0.827
   T2N0M0              19 (34.55%)   5 (9.80%)       0.004
   T2N1M0              26 (47.27%)   35 (68.63)      0.249
  Chemotherapy                                       
   1 cycle             /             6 (11.76%)      
   2 cycles            /             18 (35.29%)     
   3 cycles            /             27 (52.95%)     
  Radiotherapy                                       
   2D-CRT              33 (60.00%)   14 (27.45%)     0.006
   IMRT                22 (40.00%)   37 (72.55%)     0.051

RT: radiotherapy.

CCRT: concurrent chemoradiotherapy.

2D-CRT: two-dimensional conventional radiotherapy.

IMRT: intensity-modulated radiotherapy.

QoL of RT versus CCRT for the whole group {#s2_2}
-----------------------------------------

RT had higher mean scores in global QoL, physical functioning, role functioning, and emotional functioning but lower mean scores in fatigue, insomnia, financial problems and weight gain compared with CCRT (Table [2](#T2){ref-type="table"}). Clinically relevant QoL was significant on the scales of role functioning, emotional functioning, fatigue, insomnia, financial problems, and weight gain based on clinical interpretation (difference in mean scores ≥10 points). The result indicates that CCRT adversely affects the QoL of patients with stage II NPC versus RT.

###### Mean quality of life scores of RT versus CCRT for the whole group

  Scales                     RT (n = 55)   CCRT (n = 51)   T-test   *P*              
  -------------------------- ------------- --------------- -------- ------- -------- -------
  EORTC QLQ-C30                                                                      
   Global quality of life    76.67         16.15           67.81    16.92   9.082    0.000
   Physical functioning      87.39         17.67           80.26    17.23   2.102    0.038
   Role functioning          87.88         18.27           76.80    19.46   3.024    0.003
   Emotional functioning     82.73         22.79           71.90    24.55   2.356    0.020
   Cognitive functioning     77.88         27.79           69.28    22.20   1.751    0.083
   Social functioning        78.79         24.52           73.20    22.63   1.216    0.227
   Fatigue                   18.59         19.13           28.76    23.85   −2.431   0.017
   Nausea/emesis             3.03          7.92            2.29     6.68    0.520    0.604
   Pain                      10.30         15.21           15.36    14.85   −1.730   0.087
   Dyspnea                   6.06          12.97           9.15     18.95   −0.986   0.327
   Insomnia                  21.82         22.42           34.64    28.25   −2.597   0.011
   Appetite loss             8.48          16.00           7.19     15.37   0.424    0.672
   Constipation              4.85          16.25           4.58     17.66   0.083    0.934
   Diarrhea                  4.85          14.93           5.88     12.83   −0.381   0.704
   Financial problems        27.27         28.03           41.18    27.15   −2.590   0.011
  EORTC QLQ-H&N35                                                                    
   Pain                      7.12          12.05           8.17     7.54    −0.532   0.596
   Swallowing                14.09         17.41           17.48    15.21   −1.065   0.289
   Senses                    16.67         16.97           17.32    17.31   −0.196   0.845
   Speech                    6.26          10.20           5.88     9.78    0.196    0.845
   Social contact            14.70         21.03           19.61    19.42   −1.246   0.216
   Social eating             7.39          10.79           6.67     10.41   0.353    0.725
   Sexuality                 33.03         31.99           43.46    29.83   −1.733   0.086
   Teeth                     27.88         31.27           32.03    25.79   −0.747   0.457
   Opening mouth             16.97         23.89           20.26    22.19   −0.733   0.465
   Dry mouth                 39.39         28.75           39.22    28.83   0.032    0.975
   Sticky saliva             4.85          13.48           7.84     19.54   −0.924   0.358
   Coughing                  10.30         18.00           13.07    16.44   −0.825   0.411
   Feeling ill               13.33         19.88           15.69    20.39   −0.601   0.549
   Pain killers              5.45          22.92           9.80     30.03   −0.842   0.402
   Nutritional supplements   45.45         57.15           58.82    49.71   −1.281   0.203
   Feeding tube              0.00          0.00            0.00     0.00    0.000    1.000
   Weight loss               5.45          22.92           13.73    34.75   −1.435   0.155
   Weight gain               1.82          13.48           35.29    48.26   −4.783   0.000

RT: radiotherapy.

CCRT: concurrent chemoradiotherapy.

SD: standard deviation.

EORTC QOL-C30: European Organization for Research and Treatment of Cancer

Quality of Life Questionnaire-Core 30.

EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

QoL of RT versus CCRT by different radiotherapy techniques {#s2_3}
----------------------------------------------------------

In the two-dimensional conventional radiotherapy (2D-CRT) subgroup, RT (n = 33) had better QoL than CCRT (n = 14). Differences between the two groups were clinically relevant (Table [3](#T3){ref-type="table"}). Moreover, the intensity modulated radiotherapy (IMRT) subgroup had similar results between RT (n = 22) and CCRT (n = 37) (Table [4](#T4){ref-type="table"}). Despite the radiation technique used (2D-CRT or IMRT), RT resulted in better QoL versus CCRT.

###### Mean values for all scales of RT versus CCRT with 2D-CRT technique

  Scales                     RT (n = 33)   CCRT (n = 14)   T-test   *P*              
  -------------------------- ------------- --------------- -------- ------- -------- -------
  EORTC QLQ-C30                                                                      
   Global quality of life    69.95         15.30           53.57    11.65   −3.580   0.001
   Physical functioning      80.61         19.10           64.29    14.93   −2.843   0.007
   Role functioning          80.81         20.46           59.52    19.30   −3.314   0.002
   Emotional functioning     74.49         23.75           50.60    26.65   −3.043   0.004
   Cognitive functioning     66.67         30.33           47.62    22.51   −2.110   0.040
   Social functioning        66.67         24.65           48.81    19.02   −2.417   0.020
   Fatigue                   26.94         19.84           51.59    17.76   4.012    0.000
   Nausea/emesis             4.04          9.35            4.76     7.81    0.253    0.801
   Pain                      13.64         17.90           28.57    10.19   2.916    0.006
   Dyspnea                   9.09          15.08           16.67    17.30   1.508    0.139
   Insomnia                  28.28         20.62           61.90    22.10   5.006    0.000
   Appetite loss             14.14         18.69           19.05    17.12   0.843    0.404
   Constipation              8.08          20.46           4.76     12.10   −0.564   0.575
   Diarrhea                  7.07          18.18           14.29    17.12   1.265    0.212
   Financial problems        39.39         28.20           57.14    20.37   2.125    0.039
  EORTC QLQ-H&N35                                                                    
   Pain                      10.86         14.05           13.10    7.10    0.563    0.576
   Swallowing                22.22         18.00           33.93    14.05   2.165    0.036
   Senses                    23.74         17.69           28.57    17.82   0.855    0.397
   Speech                    9.43          11.82           13.49    10.83   1.104    0.276
   Social contact            24.24         22.57           39.88    18.83   2.275    0.028
   Social eating             12.12         11.72           14.29    13.30   0.556    0.581
   Sexuality                 47.47         30.08           72.62    30.39   2.613    0.012
   Teeth                     40.40         32.01           54.76    21.11   1.537    0.131
   Opening mouth             27.27         25.62           33.33    18.49   0.799    0.429
   Dry mouth                 54.55         23.30           66.67    18.49   1.896    0.067
   Sticky saliva             7.07          16.15           16.67    21.68   1.490    0.152
   Coughing                  10.10         17.65           21.43    16.57   2.048    0.046
   Feeling ill               18.18         20.57           33.33    18.49   2.483    0.019
   Pain killers              3.03          9.73            2.38     8.91    −0.214   0.831
   Nutritional supplements   21.21         20.10           28.57    12.10   1.544    0.131
   Feeding tube              0.00          0.00            0.00     0.00    0.000    1.000
   Weight loss               2.02          8.08            14.29    17.12   3.359    0.002
   Weight gain               1.01          5.80            4.76     12.10   1.107    0.285

2D-CRT: two-dimensional conventional radiotherapy.

RT: radiotherapy.

CCRT: concurrent chemoradiotherapy.

SD: standard deviation.

EORTC QOL-C30: European Organization for Research and Treatment of Cancer

Quality of Life Questionnaire-Core 30.

EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

###### Mean values for all scales of RT versus CCRT with IMRT technique

  Scales                     RT (n = 22)   CCRT (n = 37)   T-test   *P*              
  -------------------------- ------------- --------------- -------- ------- -------- -------
  EORTC QLQ-C30                                                                      
   Global quality of life    86.31         12.49           79.04    16.42   1.481    0.146
   Physical functioning      97.62         8.91            89.90    14.45   2.229    0.032
   Role functioning          98.81         4.45            86.87    16.01   3.941    0.000
   Emotional functioning     92.26         17.74           87.63    14.75   0.927    0.359
   Cognitive functioning     95.24         10.19           84.34    13.14   2.764    0.008
   Social functioning        98.81         4.45            87.88    14.60   3.895    0.000
   Fatigue                   4.76          7.18            15.82    20.04   −2.779   0.008
   Nausea/emesis             2.38          6.05            0.51     2.90    1.107    0.285
   Pain                      5.95          8.29            9.09     13.24   −0.982   0.332
   Dyspnea                   2.38          8.91            6.06     19.46   −0.675   0.503
   Insomnia                  11.90         24.83           22.22    24.53   −1.314   0.196
   Appetite loss             0.00          0.00            2.02     11.61   −0.647   0.521
   Constipation              0.00          0.00            5.05     20.62   −0.911   0.367
   Diarrhea                  2.38          8.91            3.03     9.73    −0.214   0.831
   Financial problems        7.14          14.19           27.27    25.62   −3.438   0.001
  EORTC QLQ-H&N35                                                                    
   Pain                      2.38          5.09            3.79     5.55    −0.814   0.420
   Swallowing                2.98          6.21            6.31     9.78    −1.404   0.169
   Senses                    8.33          8.65            13.13    16.01   −1.054   0.298
   Speech                    1.59          4.03            3.37     8.09    −0.779   0.440
   Social contact            0.00          0.00            6.82     12.58   −3.114   0.004
   Social eating             0.48          1.78            3.43     7.66    −2.089   0.043
   Sexuality                 4.76          10.19           27.78    20.27   −5.164   0.000
   Teeth                     7.14          14.19           16.16    20.62   −1.727   0.093
   Opening mouth             2.38          8.91            9.09     15.08   −1.894   0.066
   Dry mouth                 19.05         21.54           24.24    26.71   −0.643   0.523
   Sticky saliva             2.38          8.91            5.05     18.86   −0.504   0.617
   Coughing                  14.29         21.54           11.11    15.96   0.561    0.578
   Feeling ill               2.38          8.91            11.11    19.84   −2.081   0.043
   Pain killers              0.00          0.00            4.04     11.05   −2.101   0.044
   Nutritional supplements   0.00          0.00            17.17    16.92   −5.831   0.000
   Feeding tube              0.00          0.00            0.00     0.00    0.000    1.000
   Weight loss               2.38          8.91            1.01     5.80    0.628    0.533
   Weight gain               0.00          0.00            11.11    15.96   −4.000   0.000

IMRT: intensity-modulated radiotherapy.

RT: radiotherapy.

CCRT: concurrent chemoradiotherapy.

SD: standard deviation.

EORTC QOL-C30: European Organization for Research and Treatment of Cancer

Quality of Life Questionnaire-Core 30.

EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

Comparisons of QoL scales by different chemotherapy cycles {#s2_4}
----------------------------------------------------------

In the CCRT subgroup, 6 patients received 1 cycle of concurrent chemotherapy, 18 patients received 2 cycles of concurrent chemotherapy, and 27 patients received 3 cycles of concurrent chemotherapy. Survivors who received 1 cycle of concurrent chemotherapy had worse QoL outcomes than survivors who received 2 cycles of concurrent chemotherapy. Patients who received 3 cycles of concurrent chemotherapy had the best QoL outcomes (Table [5](#T5){ref-type="table"}). Differences among most scales were clinically relevant. The unexpected results may indicate that survivors who are not tolerant of concurrent chemotherapy will have a worse QoL.

###### Comparisons of mean values for all scales by different chemotherapy cycles

  Scales                     1 cycle CT (n = 6)   2 cycles CT (n = 18)   3 cycles CT (n = 27)   F-test   *P*                      
  -------------------------- -------------------- ---------------------- ---------------------- -------- ------- ------- -------- -------
  EORTC QLQ-C30                                                                                                                   
   Global quality of life    54.17                10.21                  66.67                  13.71    72.12   18.85   3.023    0.058
   Physical functioning      57.78                15.01                  80.00                  14.99    86.41   14.79   9.048    0.000
   Role functioning          58.33                20.41                  75.00                  17.39    83.97   15.97   5.884    0.005
   Emotional functioning     47.22                22.77                  67.13                  27.19    81.73   17.80   6.687    0.003
   Cognitive functioning     36.11                16.39                  69.44                  22.32    78.21   13.96   13.836   0.000
   Social functioning        47.22                16.39                  65.74                  23.20    85.26   15.15   12.769   0.000
   Fatigue                   50.00                15.32                  33.95                  24.84    19.66   21.15   5.493    0.007
   Nausea/emesis             2.78                 6.80                   4.63                   9.58     0.00    0.00    3.047    0.057
   Pain                      27.78                13.61                  16.67                  15.12    10.90   13.29   3.737    0.031
   Dyspnea                   16.67                18.26                  5.56                   12.78    8.97    22.23   0.785    0.462
   Insomnia                  55.56                17.21                  40.74                  24.40    24.36   29.15   4.309    0.019
   Appetite loss             16.67                18.26                  7.41                   14.26    3.85    14.38   1.864    0.166
   Constipation              0.00                 0.00                   1.85                   7.86     7.69    23.68   0.798    0.456
   Diarrhea                  11.11                17.21                  5.56                   12.78    5.13    12.26   0.528    0.593
   Financial problems        55.56                17.21                  37.04                  25.28    39.74   29.84   1.079    0.348
  EORTC QLQ-H&N35                                                                                                                 
   Pain                      13.89                6.80                   7.87                   6.69     7.05    8.06    2.070    0.138
   Swallowing                36.11                13.61                  20.37                  14.64    10.26   10.62   11.381   0.000
   Senses                    30.56                19.48                  19.44                  16.42    12.82   16.54   2.927    0.063
   Speech                    14.81                9.07                   4.32                   9.44     5.13    9.55    2.998    0.059
   Social contact            47.22                17.21                  21.30                  17.44    11.22   14.52   12.709   0.000
   Social eating             21.11                14.25                  4.07                   7.97     4.87    8.55    8.724    0.001
   Sexuality                 91.67                20.41                  48.15                  28.52    28.21   17.49   20.327   0.000
   Teeth                     55.56                17.21                  37.04                  22.55    21.79   24.84   5.952    0.005
   Opening mouth             44.44                17.21                  20.37                  16.72    14.10   23.42   5.291    0.008
   Dry mouth                 61.11                25.09                  38.89                  23.57    33.33   31.27   2.388    0.103
   Sticky saliva             11.11                17.21                  9.26                   19.15    6.41    21.12   0.190    0.828
   Coughing                  27.78                13.61                  11.11                  16.17    11.54   16.17   2.811    0.070
   Feeling ill               27.78                13.61                  20.37                  23.26    8.97    17.78   3.177    0.051
   Pain killers              0.00                 0.00                   3.70                   10.78    3.85    10.86   0.363    0.698
   Nutritional supplements   22.22                17.21                  18.52                  17.04    19.23   16.79   0.109    0.897
   Feeding tube              0.00                 0.00                   0.00                   0.00     0.00    0.00    0.000    1.000
   Weight loss               16.67                18.26                  5.56                   12.78    1.28    6.54    5.013    0.011
   Weight gain               0.00                 0.00                   11.11                  16.17    15.38   16.95   2.378    0.104

CT: chemotherapy.

SD: standard deviation.

EORTC QOL-C30: European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30.

EORTC QOL-H&N35: The EOTRC Quality of Life Questionnaire-Head and Neck 35.

DISCUSSION {#s3}
==========

The study suggests that RT has better outcomes in global QoL and functional scales of EORTC QLQ-C30 compared with CCRT. The result might help clinicians make better treatment decisions and provide information to health workers on which health services are most beneficial.

Different questionnaires were used for QoL assessment in NPC patients. A few studies used the EORTC QLQ-C30 questionnaire and the EORTC QLQ-H&N35 questionnaire \[[@R10]--[@R13]\]. Some studies used the Functional Assessment of Cancer Therapy-General (FACT-G) scale, the Functional Assessment of Cancer Therapy-Head and Neck (FACT-H&N) module \[[@R14], [@R15]\], and the Functional Assessment of Cancer Therapy-Nasopharyngeal (FACT-NP) subscale \[[@R16]\]. Other studies used the MOS 36-item short-form health survey (SF-36) \[[@R17], [@R18]\] and the University of Washington Quality of Life Questionnaire \[[@R19]\]. Recently, an NPC-specific scale (QoL-NPC) was developed to assess the physical functioning and health status of Chinese NPC patients \[[@R20]\]. However, FACT-NP has not been updated. SF-36 and the University of Washington Quality of Life Questionnaire are not specific questionnaires for QoL assessment in head-and-neck cancer patients, and QoL-NPC should be further evaluated by a large sample from different centers.

In this study, we used EORTC QLQ-C30 and the EORTC QLQ-H&N35 for QoL assessment because the two questionnaires are comprehensive. The EORTC QLQ-C30 contains a range of QoL issues related to different cancer patients, including head-and-neck cancer. The EORTC QLQ-C30 has been translated into many languages and is a widely used questionnaire. The QLQ-H&N35 is used to assess the QoL of patients with head-and-neck cancer specifically. The EORTC QLQ-C30 and the EORTC QLQ-H&N35 questionnaires are valid, internally consistency, and reliable in patients from different nations and were tested in large patient groups \[[@R21]\]. The Chinese version of the EORTC QLQ-C30 and the EORTC QLQ-H&N35 were previously tested, confirmed, and validated by some studies \[[@R11]--[@R13]\].

Our study showed no significant difference between RT and CCRT groups, except for weight gain reported in the EORTC QLQ-H&N35 questionnaire. The potential reasons are the following: (1) The EORTC QLQ-H&N35 might have some limitations in assessing QoL of NPC patients, although the EORTC QLQ-H&N35 is a specific questionnaire for assessing the QoL of head-and-neck cancer patients. NPC is different from other head-and-neck cancers because of its location, biological characteristics, and treatment. NPC survivors might experience deafness, otitis media, symptoms from temporal lobe injury, and hypopituitarism after radiotherapy. The EORTC QLQ-H&N35 does not deal with these adverse effects well enough. (2) CCRT was suggested to cause statistically significantly more acute toxic effects but similar late toxic effects compared with RT \[[@R4]\]. This outcome might be interpreted as the result of the few differences between RT and CCRT observed in the symptom scales of the EORTC QLQ-H&N35.

Previous studies mainly analyzed the effect of different radiotherapy techniques (IMRT vs. 2D-CRT) on QoL \[[@R11]--[@R13]\]. Only one study mentioned the effect of chemotherapy on QoL \[[@R10]\]. The above study found that concurrent chemotherapy adversely affected five symptom scales, but did not affect global QoL and functional scales. However, our study observed that concurrent chemotherapy adversely affected not only symptom scales but also global QoL and functional scales. Our results showed that CCRT had higher scores for fatigue and insomnia than did RT. Fatigue and insomnia might be caused by chemotherapy and contribute to loss of physical functioning, role functioning, and emotional functioning. The results of 2D-CRT and IMRT subgroup analysis further confirmed the above conclusion.

Some studies discussed the impact of financial problems on QoL \[[@R14], [@R22]\]. These studies found that financial difficulties adversely affect QoL. CCRT will increase the expenses of NPC treatment and eventually increase the financial difficulties of individuals in developing countries such as China. Consequently, CCRT adversely affects QoL. But, the relation between financial problems and QoL is still unclear. Further controlled studies should be performed to test the impact of financial difficulties on QoL.

Our result shows that CCRT adversely affects QoL. Thus, we hypothesize that patients who receive more cycles of chemotherapy will experience worse QoL. However, subgroup analyses of the effect of different chemotherapy cycles on QoL show an opposite result. Survivors who received 1 cycle of concurrent chemotherapy had worse QoL outcomes than survivors who received 2 cycles of concurrent chemotherapy. Patients who received 3 cycles of concurrent chemotherapy had the best QoL outcomes.

The potential interpretations are the following: (1) The 6 patients who received 1 cycle of concurrent chemotherapy received only 1 cycle because of serious toxicity during treatment. Serious toxicity made the 6 patients' recovery worse. However, survivors who received 2 or 3 cycles of concurrent chemotherapy better tolerated chemotherapy and recovered better. (2) The 6 patients were all irradiated by 2D-CRT, the 18 patients who received 2 cycles of concurrent chemotherapy were treated with 2D-CRT or IMRT, and the 27 patients who received 3 cycles of concurrent chemotherapy were irradiated mostly by IMRT. Use of IMRT is associated with the reduction of physician-assessed late toxicities and improved patient-reported QoL in NPC survivors \[[@R11]--[@R13]\]. (3) Only 6 patients received 1 cycle of concurrent chemotherapy; thus the sample size of the CCRT group was insufficient. The result should therefore be treated with caution, and a large sample of patients should be investigated to verify the result.

The limitations of our study must be considered: (1) Only 106 patients were enrolled in our study, and the sample size of the CCRT group was insufficient for comparisons of QoL scales by different chemotherapy cycles. (2) The QoL measurement of our study was conducted at only one time point. A more methodologically sound approach is to use a longitudinal design in which the same individuals are assessed repeatedly at various time points.

MATERIALS AND METHODS {#s4}
=====================

Study population {#s4_1}
----------------

This cross-sectional study analyzed QoL data of patients with stage II NPC in the Cancer Hospital of Guangxi Medical University from June 2008 to June 2013. Inclusion criteria were (1) pathologically proved NPC, (2) stage II NPC per the 7th Edition of the UICC/AJCC staging system, (3) Karnofsky performance status \>70, (4) receiving radical RT or CCRT, and (5) disease-free survival \>3 years. Exclusion criteria were (1) age \>70 or \<18 years, (2) recurrent or metastatic NPC, (3) receiving induced or adjuvant chemotherapy, (4) a second malignancy, except for cured skin basal cell carcinoma or early stage cervical cancer, (5) severe cerebral, cardiac, hematologic, renal, hepatic, or mental disease, and (6) incompletion of the self-reporting questionnaire.

Radiotherapy {#s4_2}
------------

Patients received 2D-CRT in two phases. In the first phase, patients were irradiated by 6-megavolt bilateral and opposing photon beams. The dose for faciocervical field and lower anterior cervical field was 36 Gy. In the second phase, the dose for primary tumor was boosted from 66 Gy to 70 Gy. The prescribed irradiation dose was 2 Gy per fraction with 5 daily fractions per week.

Patients received IMRT per the International Commission on Radiation Units and Measurements Report 62 guidelines. Gross tumor volume (GTVnx) and cervical lymph node tumor volume (GTVnd) were defined as gross shown by CT/MRI. Clinical target volume (CTV) included the GTV with a 1-cm to 1.5-cm margin, the entire nasopharyngeal space, and the positive lymph node regions. The prescribed radiation dose was 66 Gy to 70.06 Gy in 30 to 31 fractions for GTV, and 54 Gy to 60 Gy in 30 fractions for CTV with 5 daily fractions per week.

Chemotherapy {#s4_3}
------------

Patients received concurrent chemotherapy on days 1, 22, and 43 during radiotherapy. Chemotherapy regimen was cisplatin 100 mg/m^2^/d by intravenous infusion. Chemotherapy was postponed or discontinued for patients who experienced serious toxicity and could not recover before the next schedule.

QoL measurement {#s4_4}
---------------

QoL assessment used the Chinese version of the EORTC QLQ-C30 questions and the EORTC QLQ-H&N35 questions \[[@R21], [@R23]--[@R25]\]. The EORTC QLQ-C30 is a cancer-specific questionnaire containing a global QoL score, five functional scales, three symptom scales, and six single items. The QLQ-H&N35 is a site-specific questionnaire assessing QoL of head-and-neck cancer patients. The QLQ-H&N35 contains seven multiple-item and six single-item scales. The standard score of all scales ranges from 0 to 100. A high score for a global QoL or functional scale represents a high/healthy level of global QoL or functioning, whereas a high score for a symptom scale represents a symptom problem. QoL changes of ≥10 points were considered clinically relevant \[[@R26], [@R27]\].

Statistical analysis {#s4_5}
--------------------

Statistical analysis was performed using SPSS for Windows version 16.0 (SPSS Inc., Chicago, IL). The χ^2^ test was used for the comparisons of categorical data. The T-test was used to compare the mean scores of QoL between two groups. The F-test was used for the comparisons among groups. All significant tests were two-sided and *P* value \<0.05 was considered statistically significant.

CONCLUSIONS {#s5}
===========

This study suggests that CCRT degrades broad aspects of QoL for patients with stage II NPC. RT may be a better treatment choice for stage II NPC compared with CCRT. However, undetected factors still might be related to QoL. The data in this study must be tested, preferably in a prospective, randomized trial.
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